

CLAIMS

1. Use of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I) in the manufacture of a medicament for use in reducing mortality in a mammal with congestive heart failure.
2. Use according to claim 1, wherein the (R)-enantiomer of (I) is used.
3. A method for reducing mortality in a mammal with congestive heart failure, comprising administering to said mammal an effective amount of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide (I).
4. A method according to claim 3, wherein the (R)-enantiomer of (I) is administered.